THE INNOVATIVE MEDICINES INITIATIVE
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
STAKEHOLDER FORUM - SAVE THE DATE
IMI will hold its Stakeholder Forum 2014 in Brussels on Wednesday 21 May. The event is a unique opportunity to learn about and discuss IMI’s latest results, activities and plans.
- 16/04/2014 : RT @EFPIA: Parliament clears €3 billion EU medicines R&D initiative http://t.co/AlmeoeQDhN @IMI_JU @MichelGoldman #Research #Pharma
- 16/04/2014 : IMI cited in @washingtonpost article on #antibiotic #resistance http://t.co/lkNJkBmvgc
- 15/04/2014 : RT @EFPIA: EP adopted today the Council regulation on the Innovative Medicines Initiative 2 Jt. Undertaking http://t.co/fjUactxUu8 @IMI_JU…